Cardio Diagnostics Showcases AI Cardiovascular Risk Solutions at National Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.

Cardiovascular disease remains the leading cause of death globally and a significant contributor to healthcare spending in the United States. According to the American Heart Association, the total cost of cardiovascular disease in the U.S. is projected to reach $1.1 trillion by 2035. By presenting at these conferences, Cardio Diagnostics aims to demonstrate how its precision medicine approach can shift the focus from reactive treatment to proactive prevention, potentially reducing the burden on health plans and improving employee health.

The company’s Epi+Gen CHD test combines genetic and epigenetic biomarkers to assess an individual’s risk for coronary heart disease. PrecisionCHD integrates these biomarkers with clinical factors to provide a comprehensive risk score. The HeartRisk platform offers population-level analytics to help employers and plan sponsors identify high-risk groups and tailor interventions. These tools leverage artificial intelligence to analyze complex biological data, providing actionable insights that traditional risk assessments may miss.

The conferences include the 2025 National Association of Health Underwriters (NAHU) Annual Convention, the 2025 Society of Professional Benefit Administrators (SPBA) Annual Meeting, the 2025 Benefits Forum, and the 2025 Consumer Directed Health Plan (CDHP) Summit. At each event, Cardio Diagnostics will conduct demonstrations and meet with benefits decision-makers to discuss the economic and health impacts of cardiovascular risk management.

“Our participation in these conferences underscores our commitment to transforming cardiovascular care through precision medicine,” said a company spokesperson. “By engaging directly with employers and plan administrators, we can help them adopt strategies that not only save lives but also reduce healthcare costs.”

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (Core Technology) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

For more information about Cardio Diagnostics and its products, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.